Author

Akira Idogaki

Observed names: A Idogaki, A. Idogaki

OpenAlex ID: A5000882328

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

2019 · Deepak L Bhatt, Philippe Gabriel Steg, et al. · The Lancet · 212

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

2021 · Hiddo J L Heerspink, C David Sjöström, et al. · European Heart Journal · 128

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

2021 · Hiddo J.L. Heerspink, David Cherney, et al. · Kidney International · 98

Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial

2026 · Rodica Pop-Busui, Søren Rasmussen, et al. · JAMA Internal Medicine · 18

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial

2026 · Sharon L. Mulvagh, Silvio E. Inzucchi, et al. · JAMA Cardiology · 6

First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial

2026 · Nikolaus Marx, John E. Deanfield, et al. · JAMA Cardiology

Works count: 6

Citation count: 462

H-index: 5

I10-index: 4